AQR Capital Management LLC Has $159.53 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

AQR Capital Management LLC raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 31.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 480,186 shares of the company's stock after purchasing an additional 114,436 shares during the quarter. AQR Capital Management LLC owned 1.55% of Medpace worth $159,532,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Medpace during the fourth quarter valued at $30,000. SBI Securities Co. Ltd. bought a new position in Medpace in the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp raised its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after purchasing an additional 29 shares during the period. Finally, Assetmark Inc. lifted its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

Shares of Medpace stock traded up $0.53 during trading on Monday, reaching $305.64. 72,508 shares of the company's stock were exchanged, compared to its average volume of 342,317. The company has a market cap of $8.78 billion, a P/E ratio of 24.20, a PEG ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The firm's 50-day moving average price is $309.90 and its 200 day moving average price is $330.04.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the prior year, the company earned $3.20 EPS. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 20.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on MEDP shares. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and reduced their price target for the stock from $370.00 to $328.00 in a research report on Monday, April 14th. Leerink Partners initiated coverage on Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price on the stock. Leerink Partnrs upgraded Medpace to a "hold" rating in a report on Monday, March 24th. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Mizuho dropped their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.